Agilent Named to Barron's 100 Most Sustainable Companies in 2019
Agilent Technologies Inc. (NYSE: A) today announced for the second year
in a row, Agilent has been ranked among Barron's 100 Most Sustainable
Companies. The company garnered the No. 3 position, moving up 14 spots
from No. 17 the previous year.
Barron's, in partnership with Calvert Research and Management, analyzed
the 1,000 largest publicly held companies by market value in the United
States. Each company was assessed against 300 performance indicators in
five categories: shareholders, employees, customers, planet and
community.
"It's a tremendous honor for Agilent to receive this award as it's a
reflection of our longstanding commitment to sustainability," said
Agilent President and CEO Mike McMullen. "Our sustainability program
reflects our values and what we stand for as a company. It's just the
right thing to do for our team, customers, community and business."
As part of its ongoing corporate social responsibility initiatives,
Agilent:
Installed key energy and water-saving solutions in the U.S., Denmark,
Germany, Italy, Singapore and China. These projects reduced annual
electricity consumption by about 6 million MWh, which is the
equivalent to a reduction of over 3,000 tons of carbon dioxide every
year and helped us deliver a 9% reduction in our water consumption.
Commissioned lower carbon electricity generation systems at two of its
large facilities in the U.S. These generating systems convert natural
gas into electricity without combustion and will typically produce 25
percent less carbon dioxide than that from grid electricity.
Developed products that use less energy and water and produce lower
emissions. This includes Intuvo, a chromatography system that uses 50
percent less electricity.
Matched employee contributions to 600 non-profits through the Agilent
Technologies Foundation, established the Agilent Employee Assistance
Fund to support employees impacted by a natural disaster, and enabled
employees to contribute an estimated 50,000 hours to community and
charitable organizations through an expansion of our program that
allows employees to take off six days per year in paid time to
volunteer.
For more information about our sustainability initiatives, please read
our corporate social responsibility report at www.agilent.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences,
diagnostics, and applied chemical markets. With more than 50 years of
insight and innovation, Agilent instruments, software, services,
solutions, and people provide trusted answers to customers' most
challenging questions. The company generated revenues of $4.91 billion
in fiscal 2018 and employs 14,800 people worldwide. Information about
Agilent is available at www.agilent.com.
To receive the latest Agilent news, subscribe to our Newsroom.
Follow Agilent on LinkedIn,
Twitter,
and Facebook.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available on the Agilent news site at http://www.agilent.com/go/news.
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform.
Panda Health...
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024).
The campaign focuses on access to IBD care and treatment as the burden of...
The global industrial automation market in life sciences industry size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 11.4% during the forecast period. ...
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...